Newsmeme!
Discover News you didn't know existed
Portola Pharmaceuticals, Inc. today announced that results from its Phase 2 EXPLORE-Xa clinical trial of betrixaban, an investigational oral direct Factor Xa inhibitor anticoagulant, will be presented during a late-breaking results session at the American College of Cardiology's 59th Annual Scientific Session in Atlanta in March.
Scientists have determined that a new instrument known as PIB-PET is effective in detecting deposits of amyloid-beta protein plaques in the brains of living people, and that these deposits are predictive of who will develop Alzheimer's disease.
Scientists have determined that a new instrument known as PIB-PET is effective in detecting deposits of amyloid-beta protein plaques in the brains of living people, and that these deposits are predictive of who will develop Alzheimer’s disease. (PRWeb Feb 10, 2010) Read the full story at http://www.prweb.com/releases/2010/02/prweb3585704.htm
In the mountains, a 4x4 SUV is almost a necessity if you plan to drive when it’s snowy. But if you live almost anywhere else, the “gas guzzlers” are a target of green scorn.
While actual news surrounding the project has been nonexistent these past few months, the fact that the long-awaited sequel hit consoles today has us ruminating on the project nonetheless. In this feature, we examine just what we want out of a potential Bioshock movie. Videogame adaptations have an absolutely horrid track record in terms of quality, but anyone who's played Bioshock knows the ...
Thanks to President Obama, the nuke-waste repository will soon be mothballed.
( University of California - San Francisco ) Scientists have determined that a new instrument known as PIB-PET is effective in detecting deposits of amyloid-beta protein plaques in the brains of living people, and that these deposits are predictive of who will develop Alzheimer's disease.
Cerus Corporation (NASDAQ:CERS) announced today that its Phase 1 trial of red blood cells treated with the INTERCEPT Blood System met its primary endpoint, with preliminary analysis demonstrating that greater than 75 percent of treated cells continued to circulate 24 hours following transfusion. The INTERCEPT red blood cell system is a pathogen inactivation treatment the company is developing to ...
Religious Freedom—Really? I am writing in response to the January 28 story (News and Commentary, "Church Historic District Challenged in Court") about the Roman Catholic Diocese suit over the creation of the Our Lady of Hope Local Historic District. The claim that there has been...
MONROVIA, Calif.----Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation antibodies, announced today the appointment of Edgardo Baracchini, Ph.D., to chief business officer.
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |